Iodine
Iodine is an essential trace element; human studies show benefits mainly in correcting an iodine deficiency, for example for the thyroid gland and goitre.
We evaluated 155 human studies on Iodine, including 63 randomised controlled trials and 26 meta-analyses or systematic reviews; the controlled studies include 24,647 participants in total. As of 14 October 2026.
1. What Is Iodine? Occurrence, Origin and Forms
Iodine is a halogen and an essential trace element that the body cannot produce itself. It occurs in seaweed, marine fish and iodised table salt, and in the thyroid gland it is a building block of thyroid hormones. Traditionally it is used to prevent iodine deficiency and goitre.
Iodine occurs in seaweed, marine fish, seafood and iodised table salt; in soils and drinking water its distribution varies greatly by region. It is studied as a dietary supplement, as iodised salt and in fortified foods.
Industrially, iodine is obtained from iodine-containing brines and salt deposits, and partly from seaweed. Studies mainly examine potassium iodide, potassium iodate, sodium iodide and molecular iodine, either alone or in fortified foods.
Forms and Preparations Studied
- Potassium iodide
- Potassium iodate
- Sodium iodide
- Molecular iodine (I₂)
- Iodised table salt
- Seaweed and kelp preparations
Not covered on this page:
- Radioiodine (I-131) in thyroid diagnostics and therapy
- Iodine-containing skin antiseptics
- Thyroid hormone preparations such as levothyroxine
- Iodinated X-ray contrast media and iodine-containing drugs such as amiodarone
2. What Does Iodine Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Children and growth | mostly no difference | high | 7 meta-analyses · 19 controlled · 20 other | 5,551 |
| Goitre (struma) | mixed | high | 1 meta-analyses · 8 controlled · 9 other | 6,386 |
| Iodised salt and fortification programmes | mixed | low | 1 meta-analyses · 5 controlled · 10 other | 2,556 |
| Other investigations | mixed | high | 14 meta-analyses · 55 controlled · 50 other | 20,233 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Iodine, Children and Growth: Human Studies
In regions with iodine deficiency, iodised table salt was associated with better cognitive development of the children in a randomised study in Ethiopia, growth did not differ 2930. In children with mild iodine deficiency, a controlled study with iodide tablets found better scores in individual cognitive subtests 48, while another controlled study with iodide tablets in pregnant women with mild iodine deficiency saw no difference in the children's IQ 35. The findings apply to iodised table salt, iodide tablets and iodised oil. Combined preparations with other micronutrients cannot be attributed to iodine alone 13. Urinary iodine excretion is a supply parameter, not a clinical effect. Thyroid values are laboratory values, not a clinical effect. Overall, the findings are inconsistent: a benefit is seen mainly in correcting an existing iodine deficiency, not with additional administration to adequately supplied children.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Keats et al. 2021 | systematic review · 451,723 participants | Single and multiple micronutrient supplements, including iodine; Pregnancy; vs. Folic acid, iron-folic acid, multiple micronutrients, lipid-based nutrients | Low birthweight (IFA vs. folic acid): improved (average RR 0.88, 95% CI 0.78 to 0.99); Low birthweight (MMN vs. iron ± folic acid): improved (average RR 0.85, 95% CI 0.77 to 0.93) |
| 2 Levie et al. 2019 | meta-analysis · 6,180 participants | No supplement; urinary iodine and creatinine measured in pregnancy; Pregnancy, gestational weeks up to 14 relevant; vs. UI/Creat <150 µg/g versus higher values | Child verbal IQ: no difference (-0.6 point; 95% CI: -1.3 to 0.1 points; P = 0.082); Child nonverbal IQ: no difference (-0.6 point; 95% CI: -1.7 to 0.4 points; P = 0.246) |
| 3 Farebrother et al. 2018 | systematic review · 5,729 participants | Iodine fortification (iodized salt) or iodine supplements, any form/dose; any dose and regimen, not reported individually; vs. Placebo, noniodized salt, or no intervention | Mean birthweight in severe iodine deficiency: improved (MD: 200 g; 95% CI: 183, 217 g); Primary growth outcomes in other groups: no difference; Insulin-like growth factor-1 in moderate-to-mildly iodine-deficient schoolchildren: improved (MD: 38.48 ng/mL; 95% CI: 6.19, 70.76 ng/mL) |
| 4 Harding et al. 2017 | systematic review · 2,700 participants | Iodine tablets, capsules or drops, sometimes with vitamins/minerals; vs. no iodine supplementation | Perinatal mortality: improved (average RR 0.) |
| 5 Velasco et al. 2026 | systematic review · 2,528 participants | Iodine supplementation alone or with iron; 150 µg daily for 28 weeks; single dose 100 mg or 400-490 mg; Follow-up 3 to 22 months; vs. Placebo | Cognitive function (validated scales): improved (standardised mean difference 0.19, 95% confidence interval (CI) 0.04 to 0.34); Weight (kg): no difference (mean difference (MD) -0.20, 95% CI -1.92 to 1.52) |
| 7 Walsh et al. 2019 | systematic review · 1,394 participants | Iodine as iodide salt added to enteral or parenteral feeds; vs. Placebo or no supplementation | Mortality before hospital discharge: no difference (typical RR 1.01, 95% CI 0.72 to 1.42); Bayley-III cognitive composite score at 2 years: no difference (MD -0.30, 95% CI -2.44 to 1.84); Bayley-III motor composite score at 2 years: no difference (MD 0.20, 95% CI -2.15 to 2.55) |
| 16 Daniel et al. 2025 | systematic review | No iodine intervention, observation of iodine status (diet, iodized salt); Studies 2010 to 2024, NHANES data 2011-2020; vs. No intervention control; WHO threshold <150 µg/L | Offspring neurodevelopment and IQ with low maternal UIC: worsened (reduced IQ scores) |
| 21 Favara et al. 2024 | systematic review | Iodine via maternal diet/supplements | Neurodevelopment: improved |
Further studies in this area: 23 24 25 29 30 35 37 43 44 45 47 48 53 58 61 62 68 70 82 85 88 93 96 97 104 105 113 114 117 121 122 127 131 139 144 145 146 147
Iodine and Goitre (Struma): Human Studies
In iodine deficiency areas, daily iodine administration in pregnant women slowed the increase in thyroid volume compared with controls 7088. After birth, the volume fell compared with the baseline value 6566. A placebo-controlled study found no confirmed difference in thyroid volume 63. The frequency of goitre fell in Zaire in villages with iodised oil, whether given by mouth or as an injection, while it remained the same in control villages 94. A Cochrane review found a trend towards less goitre with iodised table salt, not significant in all studies 8. In breastfeeding women, the frequency of goitre fell with potassium iodide capsules or iodised salt compared with the baseline value 58. The findings apply to people with existing iodine deficiency; whether additional iodine administration is beneficial when supply is sufficient is therefore not clarified. Algae and kelp preparations as well as multi-ingredient preparations with fluctuating iodine content were not tested as pure iodine and do not allow conclusions of their own.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 5 Velasco et al. 2026 | systematic review · 2,528 participants | Iodine supplementation alone or with iron; 150 µg daily for 28 weeks; single dose 100 mg or 400-490 mg; Follow-up 3 to 22 months; vs. Placebo | Goitre: unclear (RR 0.68, 95% CI 0.15 to 3.07) |
| 8 Wu et al. 2002 | systematic review · 334 participants | Iodised salt; vs. Non-iodised salt, iodised water, iodised oil, potassium iodide vs. potassium iodate | Goitre rate: improved |
| 12 Harikrishnan et al. 2026 | systematic review | Iodine via diet/iodized salt (regions with differing iodine status); vs. Coastal versus inland regions | Prevalence of goiter: improved |
| 58 Gebreegziabher et al. 2019 | randomised controlled · 106 participants | Potassium iodide capsule vs. iodized salt; 225 µg iodine daily as capsule or iodized salt weekly; 26 weeks; vs. Potassium iodide capsule vs. iodized salt | Goiter prevalence: unclear (significantly decreased) |
| 63 Censi et al. 2019 | randomised controlled · 90 participants | potassium iodide tablets (iodide) versus placebo; 225 µg/day; from enrollment until 8 weeks after delivery; vs. placebo control group (3:2 randomization) | thyroid volume (TV): no difference (+Δ7.43% in the Iodine group, and by +Δ11.17% in the Placebo group) |
| 65 Reinhardt et al. 1998 | randomised controlled · 70 participants | potassium iodide; 50 µg or 250 µg daily; 8 months postpartum, starting 5 days after delivery; vs. 50 µg versus 250 µg; plus untreated group in study I | thyroid volume: unclear (25.4 +/- 1.5 ml (mean +/- sem) to 18.2 +/- 1.25 p <0.001); thyroid volume without iodine: unclear (29 +/- 2.2 ml; at 3 months 27.5 +/- 3.0 ml) |
| 66 Antonangeli et al. 2002 | randomised controlled · 67 participants | iodide (potassium iodide) daily; 200 µg/day (group A) vs. 50 µg/day (group B); daily up to 6 months after delivery; vs. 200 µg iodide vs. 50 µg iodide daily | thyroid volume during gestation: unclear (slight but not significant increase in TV during gestation was observed only in group B); thyroid volume after delivery: unclear (final TV being significantly reduced with respect to the initial volume in group A) |
| 70 Pedersen et al. 1993 | randomised controlled · 54 participants | iodine supplementation; 200 µg iodine/day; from weeks 17-18 of pregnancy until 12 months after delivery; vs. control group without iodine | thyroid size: improved |
Further studies in this area: 88 89 94 99 111 112 113 127 135 144
Iodine, Iodised Salt and Fortification Programmes: Human Studies
In regions with iodine deficiency, iodised table salt improved iodine status: a randomised controlled study with over a thousand pregnant women and their children in Ethiopia found less iodine deficiency in mothers and children 30. Another randomised study in Ethiopia advised mothers on the use of iodised salt and found a higher urinary iodine excretion in the children of the intervention group than in the control group 34. Both studies took place in regions with existing iodine deficiency, not with adequate supply. With mixtures, the attribution to iodine alone is limited: salt double-fortified with iodine and folic acid did not change salt intake 41, and a salt fortified four times with iron, iodine, folic acid and vitamin B12 did not differ from salt double-fortified with iron and iodine in acceptance, consumption and sensory distinguishability 64. The strength of evidence is low; the controlled studies are small to medium-sized and largely limited to Ethiopia, while the remaining work mainly describes supply and laboratory values such as urinary iodine excretion and some remained without a control group.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 23 Bath et al. 2022 | systematic review | Iodine from iodized salt and foods; vs. Intake versus dietary recommendations | National surveys including iodized salt in estimation: unclear (32% of national surveys (n = 7)) |
| 30 Mohammed et al. 2020 | randomised controlled · 1,220 participants | Iodized salt via early market access; from conception to child age 2–13 months; vs. control with later market access to iodized salt | Iodine deficiency (UIC <50 μg/L) in mothers prepartum: improved (28% vs. 41%, p < .05); Iodine deficiency (UIC <50 μg/L) in children: improved (13% vs. 20%, p < .05) |
| 34 Ferede et al. 2026 | randomised controlled · 834 participants | Iodized table salt (iodide) in households; mean iodide content 45.3 ppm in table salt; 15-month intervention; vs. intervention vs. control group (cluster randomized) | iodide content in table salt: unclear (45.3 ppm) |
| 41 Nane et al. 2026 | randomised controlled · 342 participants | Double-fortified salt with iodine and folic acid (DFS-IoFA); vs. Salt intake before versus during intervention | Discretionary salt intake: no difference (8.7 ± 4.3 g/d before and 8.8 ± 4.0 g/d during the intervention (P = 0.8)) |
| 64 Guetterman et al. 2025 | randomised controlled · 77 participants | Quadruple-fortified salt (iron, iodine, folic acid, vitamin B12) vs. double-fortified salt vs. iodized salt; 3 weeks (1 week per salt type); vs. Double-fortified salt and iodized salt | Acceptability (overall hedonic rating): no difference (QFS: 7.8 (0.7) compared with DFS: 7.7 (1.2); P = 0.68); Weighed household salt use: no difference; Sensory discrimination in triangle tests: no difference |
| 91 Pattisapu et al. 2024 | controlled · 83 participants | Double fortified salt (folic acid plus iodine); approximately 300 µg/d folic acid; 4 months; vs. pre-post design, no control group | median serum folate: improved (increased from 14.6 (IQR, 11.2-20.6) nmol/L at baseline to 54.4 (IQR, 43.5-54.4) nmol/L) |
| 95 Catumbela et al. 2025 | cross-sectional study · 2,250 participants | Household iodized salt; Adequate iodization 15-40 ppm; vs. Pregnant vs. non-pregnant; provincial strata | Households using iodized salt: unclear (74.3%); Households with adequately iodized salt (15-40 ppm): unclear (29.2%) |
| 96 Jamal¹ et al. 2026 | cross-sectional study · 300 participants | Iodized salt (household use); vs. Children with above-average vs. below-average IQ | Maternal knowledge of iodized salt: improved |
Further studies in this area: 99 111 113 114 117 128 140 146
Iodine: Further Outcomes in Studies
In iodine deficiency areas, iodised table salt raised urinary iodine excretion 829. With iodine administration, thyroglobulin was lower or rose less than in the control groups 4854556370. The infants' urinary iodine excretion remained the same under the lower iodine dose given to the mother as under placebo 82, and potassium iodide capsules and iodised salt did not differ in breast milk and urinary iodine in breastfeeding women 85. Urinary iodine excretion fell in one study under a palaeolithic diet that excludes iodised table salt and dairy products, compared with a diet according to the Nordic recommendations 84. The robustness is inconsistent, because the studies examined very different forms — iodide, iodate, molecular iodine, iodised table salt, iodised oil and iodine-rich foods — in some cases small groups and often only over months. Some of the investigations concerned combined preparations with iron, folic acid, zinc or other micronutrients, whose findings cannot be attributed to iodine alone 1910. It remains open how an additional iodine administration affects people who are already adequately supplied and whether the observed laboratory changes also have clinical consequences.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Keats et al. 2021 | systematic review · 451,723 participants | Single and multiple micronutrient supplements, including iodine; Pregnancy; vs. Folic acid, iron-folic acid, multiple micronutrients, lipid-based nutrients | Maternal anaemia (IFA vs. folic acid): improved (average risk ratio (RR) 0.52, 95% CI 0.41 to 0.66); Stillbirths (MMN vs. iron ± folic acid): improved (average RR 0.91; 95% CI 0.86) |
| 4 Harding et al. 2017 | systematic review · 2,700 participants | Iodine tablets, capsules or drops, sometimes with vitamins/minerals; vs. no iodine supplementation | Postpartum hyperthyroidism: improved (average risk ratio (RR) 0.32; 95% confidence interval (CI) 0.11 to 0.91); Digestive intolerance in pregnancy: worsened (average RR 15.33; 95% CI 2.07 to 113.70); Hypothyroidism in pregnancy: no difference (average RR 1.90; 95% CI 0.57 to 6.38) |
| 5 Velasco et al. 2026 | systematic review · 2,528 participants | Iodine supplementation alone or with iron; 150 µg daily for 28 weeks; single dose 100 mg or 400-490 mg; Follow-up 3 to 22 months; vs. Placebo | Hypothyroidism: improved (risk ratio (RR) 0.03, 95% CI 0.00 to 0.23); All-cause mortality in infants: improved (RR 0.32, 95% CI 0.14 to 0.73) |
| 6 Haroon et al. 2026 | meta-analysis · 2,257 participants | Preoperative iodine solution; vs. Control group without iodine solution | Intraoperative estimated blood loss: no difference (mean difference = -24.6 mL, 95% confidence interval: -56.2, 7.0); Operative time: no difference (mean difference = -2.3 minutes, 95% confidence interval: -10.6, 6.0); Endocrine-related complications: no difference (odds ratio = 0.85, 95% confidence interval: 0.42, 1.74) |
| 8 Wu et al. 2002 | systematic review · 334 participants | Iodised salt; vs. Non-iodised salt, iodised water, iodised oil, potassium iodide vs. potassium iodate | Urinary iodine excretion: improved |
| 9 Abe et al. 2016 | systematic review · 52 participants | Multiple-micronutrient supplement (three or more micronutrients); vs. Placebo or no supplementation | Maternal anaemia: improved |
| 10 Lall et al. 2026 | systematic review | Salt fortified with iodine and other nutrients; vs. Control groups without fortified salt | Hemoglobin concentration: improved (0.36 (0.22, 0.50)); Odds of anemia: improved; Odds of iron deficiency anemia: improved |
| 11 Nazeri et al. 2026 | systematic review | Iodized salt, iodine-containing supplements, iodized oil; vs. No uniform comparison; iodine status or supplementation vs. control | Postpartum depressive symptoms and anhedonia with low iodine intake: worsened; Effect of supplementation/fortification on maternal mood: unclear |
Further studies in this area: 12 13 14 15 16 17 18 19 20 22 23 25 26 27 28 29 31 32 33 36 37 38 39 40 43 44 45 46 48 49 50 51 52 54 55 56 57 58 59 60 61 63 65 66 67 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 85 86 87 88 89 90 92 94 95 98 99 100 101 102 103 104 106 107 108 109 110 112 115 116 118 119 120 121 123 124 125 126 127 128 129 130 132 133 134 136 137 138 139 140 141 142 143 144 145 148 149
4. How Is Iodine Dosed? Preparation, Dose and Duration in Studies
The studies predominantly tested oral forms: potassium iodide tablets, potassium iodate, iodised table salt and iodised oil, and in some cases also molecular iodine. Some investigations gave iodine via fortified foods or as part of multinutrient preparations. Algae and kelp preparations have a fluctuating iodine content and were not tested as pure iodine.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Supplement with myo-inositol, probiotics and micronutrients incl. iodine | — | up to 12 months | 27 |
| MMN with 250 µg iodine or SQ-LNS with similar nutrient content | 250 µg/d iodine (MMN); LNS similar; IFA: 60 mg Fe + 400 µg folic acid | until childbirth (UIC measured at week 36) | 28 |
| Iodized salt (early market access) | — | pregnancy until child age 2–13 months | 29 |
| Iodized salt via early market access | — | from conception to child age 2–13 months | 30 |
| Quintuply-fortified salt (QFS) with iodine, iron, zinc, vitamin B12, folic acid vs standard iodized salt | — | 12 months | 31 |
| Quintuply-fortified salt (QFS) vs. iodized salt | Salt disappearance 6.0 g/adult female equivalent/day; iodine dose not reported | 12 months (assessments at 0, 6 and 12 months) | 32 |
| Daily prenatal multiple micronutrient supplement containing iodine vs. iron and folic acid (FeFol) | 300 µg iodine daily | Pregnancy until 30 weeks' gestation; follow-up to 24 weeks postpartum | 33 |
| Iodized table salt (iodide) in households | mean iodide content 45.3 ppm in table salt | 15-month intervention | 34 |
| 200 µg iodine orally once daily as a tablet until delivery vs. placebo | 200 µg iodine once daily, adherence 87% | from enrolment (mean gestational age 10·7 weeks) to delivery; children re-assessed at age 5–6 years | 35 |
| Oral iodized oil (OIO) vs. poppy-seed oil placebo | — | First dose at 8 weeks, boosters at 4-week intervals, follow-up at 6 months | 36 |
| Daily oral iodine 200 µg or placebo until delivery | 200 µg iodine daily orally | Until delivery, compliance 88% | 37 |
| Quintuply-fortified salt (QFS) vs. iodized salt (IS) | — | 12 months | 38 |
| About 10 g iodized salt daily versus noniodized salt with low-iodine or noniodine diet | about 10 grams of iodized salt daily | dietary intervention 24 months; recurrence assessed 12 months after ATD withdrawal | 39 |
| Iodized salt with 32 ppm iodine, fortified with folic acid | 7.8 ± 1.8 g salt/day; folic acid 99, 36 or 0 ppm | 26 weeks, bi-weekly delivery | 40 |
| Iodized oil (iodine form/dose not reported); plus selenium or placebo | not reported | 12 months | 42 |
5. Is Iodine Safe? Side Effects in Studies
In the studies on iodine administration in iodine-deficient areas, predominantly no or only mild, temporary side effects were reported 8636566. In a controlled study with iodide tablets in pregnant women, adverse events occurred with similar frequency in both groups 35.
| Study | Reported side effects |
|---|---|
| 4 Harding et al. 2017 | Less postpartum hyperthyroidism, more digestive intolerance in pregnancy |
| 5 Velasco et al. 2026 | No study reported adverse events related to iodine |
| 6 Haroon et al. 2026 | Endocrine complications, hypocalcemia, hematoma, recurrent laryngeal nerve injury similar to control |
| 8 Wu et al. 2002 | No adverse effects observed |
| 9 Abe et al. 2016 | none reported, no data on adverse effects |
| 11 Nazeri et al. 2026 | Potential increase in emotional distress under specific conditions (supplementation) |
| 13 Lv et al. 2026 | not reported |
| 25 Zhou et al. 2013 | Safety assessed, no specific findings reported |
| 32 Goh et al. 2025 | not reported |
| 35 Gowachirapant et al. 2017 | adverse events similar between groups: 24 vs. 28 women (abortion, blighted ovum, intrauterine death) |
| 37 Verhagen et al. 2020 | Slightly greater decrease in free and total thyroxine in the iodine group (p < 0.05) |
| 40 Tessema et al. 2026 | No group-wise differences in reported adverse events |
6. What Remains Open: Limits of the Evidence
- The benefit has been shown mainly for correcting an existing iodine deficiency; the effect of additional iodine administration when supply is adequate is open.
- Many controlled studies are small to medium-sized and predominantly limited to individual regions such as Ethiopia.
- The studies tested very different iodine forms and preparations, which makes direct comparison difficult.
- Findings on combination preparations with other micronutrients cannot be attributed to iodine alone.
- Whether observed changes in laboratory values such as urinary iodine excretion also have clinical consequences remains unclear.
7. Bottom Line: What Is Established About Iodine
Iodine is an essential trace element that the body cannot produce itself, and in the thyroid gland it is a building block of thyroid hormones. Human studies show the clearest benefit in correcting an existing iodine deficiency: in iodine-deficient areas, iodine administration dampened the increase in thyroid volume during pregnancy 7088, and the frequency of goitre decreased in villages with iodised oil 94. Iodised table salt also improved the iodine status of mothers and children 30. In children in iodine-deficient regions, iodised table salt was associated with better cognitive development in a randomised study in Ethiopia, while no difference was found in growth 2930.
The findings apply to the respective form and preparation investigated, especially iodide, iodate, iodised table salt and iodised oil. Algae and kelp preparations as well as multinutrient preparations with fluctuating iodine content do not allow conclusions of their own about pure iodine.
Frequently Asked Questions
How well has Iodine been studied in humans?
We evaluated 155 human studies on Iodine, including 63 randomised controlled trials and 26 meta-analyses or systematic reviews; the controlled studies include 24,647 participants in total. As of 14 October 2026.
Does Iodine help with children and growth? What the studies show
Does Iodine help with goitre (struma)? What the studies show
Does Iodine help with iodised salt and fortification programmes? What the studies show
What is iodine studied for in human studies?
The main areas investigated are the correction of iodine deficiency, thyroid volume and the frequency of goitre. In iodine deficiency areas, controlled studies showed that iodine administration had advantages for iodine status, thyroid volume and frequency of goitre 8708894. In addition, iodine status, thyroid hormone levels and urinary iodine excretion were measured as supply and laboratory parameters.
Which iodine forms were tested in the studies?
Predominantly potassium iodide, potassium iodate, iodised table salt and iodised oil were tested, and in some cases also molecular iodine. The forms differ in absorption and effect, so findings apply only to the respective form and preparation investigated. Algae and kelp preparations have a fluctuating iodine content and were not tested as pure iodine.
Does iodine show a benefit when supply is adequate?
That is still open: in a study with breastfeeding mothers in a country with salt iodisation, the infants' urinary iodine excretion remained the same under the lower iodine dose as under placebo 82. The demonstrated benefit mainly concerns correcting an existing iodine deficiency.
How well tolerated was iodine in the studies?
What should be noted with algae and kelp preparations?
Algae and kelp preparations have a fluctuating iodine content and were not tested as pure iodine.
Sources
- 1Keats EC, Oh C, Chau T, Khalifa DS, Imdad A, Bhutta ZA · 2021
- 2Levie D, Korevaar TIM, Bath SC, Murcia M, Dineva M, Llop S et al. · 2019
- 3Effects of Iodized Salt and Iodine Supplements on Prenatal and Postnatal Growth: A Systematic ReviewFarebrother J, Naude CE, Nicol L, Sang Z, Yang Z, Jooste PL et al. · 2018
- 4Harding KB, Peña-Rosas JP, Webster AC, Yap CM, Payne BA, Ota E et al. · 2017
- 5Velasco I, Rueda-Etxebarria M, Trak-Fellermeier MA, Taylor P, Rabassa Bonet M, Chi Y et al. · 2026
- 6Haroon AM, Ghani A, Ayesh AR, Witkowiak MM, Alogakos M, Burns J et al. · 2026
- 7Walsh V, Brown JVE, McGuire W · 2019
- 8Wu T, Liu GJ, Li P, Clar C · 2002
- 9Abe SK, Balogun OO, Ota E, Takahashi K, Mori R · 2016
- 10Lall G, Zimmermann MB, Schultink W, Larson LM · 2026
- 11Nazeri P, Taghva Nakhjiri M, Chashmyazdan M, Pearce EN · 2026
- 12Harikrishnan ST, Azeez A, Reji S, Jacob DM, Al Hamdani MS, Eksheir S et al. · 2026
- 13Lv Y, Jin B, Guo J, Bu J, Chen C, Han Y et al. · 2026
- 14Aarsland TE, Aakre I, Stea TH, Henjum S, Markhus MW, Strand TA et al. · 2025
- 15Gräfe W, Scheibe S, Schwarz J, Liebig L, Voigt K, Schübel J · 2025
- 16
- 17Lopes SO, Mayer EM, Azevedo FM, Candido AC, Bittencourt JM, Morais DC et al. · 2025
- 18Wang T, Tong J, Liu Y, Liu Y, Xu H, Liu Y · 2025
- 19Nazeri P, Chashmyazdan M, Masoumi M, Bagheri M, Taghva Nakhjiri M, Shafaatdoost M et al. · 2025
- 20Leonard UM, Leydon CL, Arranz E, Kiely ME · 2024
- 21Favara G, Maugeri A, Barchitta M, Lanza E, Magnano San Lio R, Agodi A · 2024
- 22Xie Q, Zhang X, Ma J, Lu X, Zhang Y, Tong N · 2023
- 23Bath SC, Verkaik-Kloosterman J, Sabatier M, Ter Borg S, Eilander A, Hora K et al. · 2022
- 24Bougma K, Aboud FE, Harding KB, Marquis GS · 2013
- 25Zhou SJ, Anderson AJ, Gibson RA, Makrides M · 2013
- 26
- 27Chan SY, Barton SJ, Loy SL, Chang HF, Titcombe P, Wong JT et al. · 2023
- 28Adu-Afarwuah S, Arnold CD, Maleta K, Ashorn P, Ashorn U, Jorgensen JM et al. · 2021
- 29Mohammed H, Marquis GS, Aboud F, Bougma K, Samuel A · 2021
- 30Pre-pregnancy iodized salt improved children's cognitive development in randomized trial in EthiopiaMohammed H, Marquis GS, Aboud F, Bougma K, Samuel A · 2020
- 31Thompson L, Goh YE, Jamwal M, Singh BL, Brar GK, Arnold CD et al. · 2025
- 32Goh YE, Duggal M, Das R, Manger MS, Jamwal M, Singh BL et al. · 2025
- 33Eriksen KG, Andersson M, Hunziker S, Zimmermann MB, Moore SE · 2020
- 34
- 35Gowachirapant S, Jaiswal N, Melse-Boonstra A, Galetti V, Stinca S, Mackenzie I et al. · 2017
- 36Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccineTaffs RE, Enterline JC, Rusmil K, Muhilal, Suwardi SS, Rustama D et al. · 1999
- 37Verhagen NJE, Gowachirapant S, Winichagoon P, Andersson M, Melse-Boonstra A, Zimmermann MB · 2020
- 38Long JM, Goh YE, Duggal M, Das R, Manger MS, Jamwal M et al. · 2026
- 39Huang H, Shi Y, Liang B, Cai H, Cai Q, Lin R · 2018
- 40Tessema M, Nane D, Woldeyohannes M, Agbemafle I, McDonald CM, Arnold CD et al. · 2026
- 41Nane D, Fereja M, Agbemafle I, Arnold CD, Woldeyohannes M, McDonald CM et al. · 2026
- 42Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT et al. · 2003
- 43Zimmermann MB, Connolly K, Bozo M, Bridson J, Rohner F, Grimci L · 2006
- 44Huda SN, Grantham-McGregor SM, Tomkins A · 2001
- 45Bouhouch RR, Bouhouch S, Cherkaoui M, Aboussad A, Stinca S, Haldimann M et al. · 2014
- 46Manousou S, Eggertsen R, Hulthén L, Filipsson Nyström H · 2021
- 47van den Briel T, West CE, Bleichrodt N, van de Vijver FJ, Ategbo EA, Hautvast JG · 2000
- 48Gordon RC, Rose MC, Skeaff SA, Gray AR, Morgan KM, Ruffman T · 2009
- 49Herter-Aeberli I, Cherkaoui M, El Ansari N, Rohner R, Stinca S, Chabaa L et al. · 2015
- 50Traksel R, Broen J, van Henten A, Königs M, Raj A, van Eyndhoven L et al. · 2026
- 51Markhus MW, Hysing M, Midtbø LK, Nerhus I, Næss S, Aakre I et al. · 2021
- 52Thompson L, Goh YE, Jamwal M, Singh BL, Brar GK, Arnold CD et al. · 2025
- 53Nazeri P, Tahmasebinejad Z, Pearce EN, Zarezadeh Z, Tajeddini T, Mirmiran P et al. · 2021
- 54Ma ZF, Venn BJ, Manning PJ, Cameron CM, Skeaff SA · 2016
- 55Brucker-Davis F, Panaïa-Ferrari P, Gal J, Fénichel P, Hiéronimus S · 2013
- 56Hiéronimus S, Ferrari P, Gal J, Berthier F, Azoulay S, Bongain A et al. · 2013
- 57
- 58Gebreegziabher T, Woltamo T, Thomas DG, Kennedy TS, Stoecker BJ · 2019
- 59Thomson CD, Campbell JM, Miller J, Skeaff SA, Livingstone V · 2009
- 60Razmandeh R, Abbaspour F, Yazdanpanah L, Shahbazi S, Heidari M, Tabatabaei-Malazy O et al. · 2026
- 61Ares S, Saenz-Rico B, Arnaez J, Diez-Sebastian J, Omeñaca F, Bernal J · 2022
- 62Ares S, SAENZ-RICO B, ARNAEZ J, Diez-Sebastian J, Omeñaca F, Bernal J · 2021
- 63Censi S, Watutantrige-Fernando S, Groccia G, Manso J, Plebani M, Faggian D et al. · 2019
- 64Guetterman HM, Rajagopalan K, Fox AM, Johnson CB, Fothergill A, George N et al. · 2025
- 65Efficacy and safety of iodine in the postpartum period in an area of mild iodine deficiencyReinhardt W, Kohl S, Hollmann D, Klapp G, Benker G, Reinwein D et al. · 1998
- 66Antonangeli L, Maccherini D, Cavaliere R, Di Giulio C, Reinhardt B, Pinchera A et al. · 2002
- 67Nøhr SB, Jørgensen A, Pedersen KM, Laurberg P · 2000
- 68Zhou SJ, Skeaff SA, Ryan P, Doyle LW, Anderson PJ, Kornman L et al. · 2015
- 69Iodine therapy for thyroidectomy patients exhibiting high thyroid-stimulating hormone values: a randomised studyTaylor JD, Radcliffe SN, Basu PK, Atkins P · 1993
- 70Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen OS et al. · 1993
- 71Aoe S, Yamanaka C, Ohtoshi H, Nakamura F, Fujiwara S · 2021
- 72Thyroidectomy: is Lugol's iodine necessary?Coyle PJ, Mitchell JE · 1982
- 73Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O · 2016
- 74Aakre I, Tveit IB, Myrmel LS, Fjære E, Ballance S, Rosendal-Riise H · 2023
- 75The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves' hyperthyroidismChang DC, Wheeler MH, Woodcock JP, Curley I, Lazarus JR, Fung H et al. · 1987
- 76Pfeiffer CM, Fazili Z, Arnold CD, Woldeyohannes M, Nane D, Fereja M et al. · 2026
- 77Mwangi M, Molenberghs G, Njagi EN, Mwalili S, Braekers R, Florez AJ et al. · 2024
- 78Vinod Kumar M, Sankarapandian M, Erhardt J · 2022
- 79Young AE, Kemp JF, Uhlson C, Westcott JL, Ali SA, Saleem S et al. · 2021
- 80Tinna T, Ounjaijean S, Tongsong T, Traisrisilp K · 2020
- 81Moreno-Vega A, Vega-Riveroll L, Ayala T, Peralta G, Torres-Martel JM, Rojas J et al. · 2019
- 82Nazeri P, Tahmasebinejad Z, Mehrabi Y, Hedayati M, Mirmiran P, Azizi F · 2018
- 83
- 84Manousou S, Stål M, Larsson C, Mellberg C, Lindahl B, Eggertsen R et al. · 2018
- 85
- 86Correlation between Iodine Supplement in Pregnancy and Neonatal TSH LevelDandamrongrak P, Chawanpaiboon S · 2016
- 87Cobra C, Muhilal, Rusmil K, Rustama D, Djatnika, Suwardi SS et al. · 1997
- 88Glinoer D, De Nayer P, Delange F, Lemone M, Toppet V, Spehl M et al. · 1995
- 89Phillips DI, Lusty TD, Osmond C, Church D · 1988
- 90Iodine replacement in fibrocystic disease of the breastGhent WR, Eskin BA, Low DA, Hill LP · 1993
- 91Pattisapu JV, Manda VV, Kottakki MNR, Kajana PM, Kancherla V, Bhaganagarapu HR et al. · 2024
- 92Yang R, Jin Q, An D, Lv D, Wei Y, Pearce EN et al. · 2026
- 93Pharoah PO, Connolly KJ · 1991
- 94Phillips DI, Osmond C · 1989
- 95Catumbela E, de Lemos M, Nimi T, Têmbua C, Paixão JP, Kapapelo A et al. · 2025
- 96Jamal¹ H, Ijaz² F, Ullah³ I, Din ZU, Ambreen S, Ullah I · 2026
- 97Atukunda P, Muhoozi GK, Diep LM, Berg JP, Westerberg AC, Iversen PO · 2021
- 98Machado A, Gonçalves C, Moreira P, Pinho O, Padrão P, Silva-Santos T et al. · 2023
- 99
- 100Eminoğlu DÖ, Laloglu E, Kasali K, Aydin T, Bulut E, Yaliniz G et al. · 2025
- 101Urinary iodine excretion in mothers and their breast-fed children in relation to other childhood nutritional parametersAkanji AO, Mainasara AS, Akinlade KS · 1996
- 102Aakre I, Vogt EC, Myrmel LS, Lundebye AK, Helland OB, Henjum S et al. · 2026
- 103Bandyopadhyay S, Roy AK, Baker S, Stephenson KK, Ge X, Wang Y et al. · 2025
- 104Alemu R, Tafere K, Gashu D, Joy E, Bailey E, Lark R et al. · 2025
- 105Liu Z, Liu Y, Yang J, Yan L, Li Q, Gao Y · 2025
- 106Casey BM, Mele L, Peaceman AM, Varner MW, Reddy UM, Wapner RJ et al. · 2024
- 107Wang J, Gao Y, Zong Y, Gao W, Wang X, Sun J et al. · 2023
- 108Levie D, Bath SC, Guxens M, Korevaar TIM, Dineva M, Fano E et al. · 2020
- 109Manousou S, Carlsson LMS, Eggertsen R, Hulthén L, Jacobson P, Landin-Wilhelmsen K et al. · 2018
- 110Mercier F, Bonal M, Fanget F, Maillard L, Laplace N, Peix JL et al. · 2018
- 111
- 112
- 113Delić T, Karanović Štambuk S · 2026
- 114Grossklaus R, Liesenkötter KP, Lawrenz B, Thieme F · 2026
- 115Zugravu CA, Petre M, Constantin C · 2026
- 116Milionis C, Koukkou EG, Markou KB, Ilias I · 2026
- 117
- 118
- 119López-Sebastiani V, Quiroz-Cornejo KV, Arellano-Salazar MP, Monje-Bolivar F, Samillan VJ · 2026
- 120Finta H, Avram C, Buicu CF, Ceana DE, Moldovan I, Ruta F · 2026
- 121Khudair A, Khudair A, Niinuma SA, Habib H, Butler AE · 2025
- 122
- 123Malhotra A, Lakade A · 2025
- 124Li S, Xu Q, Wang S, Peng H, Liu Y · 2025
- 125Herrero Jiménez MP, Del Pozo de la Calle S, Cuadrado Vives C, Escobar Sáez D · 2025
- 126Hart KH, Hill AJ, Gonzalez JT, de la Hunty A, Gallagher AM, Stanner SA · 2025
- 127Moreno-Reyes R, Fuentes Peña C, Nuñez JF, Sánchez MB, Carvajal JJ, Roble K et al. · 2025
- 128
- 129Vergatti A, Abate V, Garofano F, Fiore A, De Filippo G, Strazzullo P et al. · 2025
- 130English K, Uwibambe C, Daniels P, Dzukey E · 2025
- 131Godfrey KM, Costello P, El-Heis S · 2025
- 132Huang L, Huhulea EN, Enwere C, Aifuwa E, Frishman WH, Aronow WS · 2025
- 133Robinson SR, Trivedi MS, Fayet-Moore F · 2025
- 134Zugravu C, Petre M, Constantin C · 2025
- 135Street ME, Shulhai AM, Petraroli M, Patianna V, Donini V, Giudice A et al. · 2024
- 136Shulhai AM, Rotondo R, Petraroli M, Patianna V, Predieri B, Iughetti L et al. · 2024
- 137Carretero-Krug A, Montero-Bravo A, Morais-Moreno C, Puga AM, Samaniego-Vaesken ML, Partearroyo T et al. · 2024
- 138Cyna W, Wojciechowska A, Szybiak-Skora W, Lacka K · 2024
- 139
- 140
- 141Hu S, Rayman MP · 2017
- 142
- 143
- 144Pearce EN, Lazarus JH, Moreno-Reyes R, Zimmermann MB · 2016
- 145Taylor PN, Vaidya B · 2016
- 146Vanderpump M · 2014
- 147
- 148Negro R, Soldin OP, Obregon MJ, Stagnaro-Green A · 2011
- 149
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.